Global Vitiligo Market Forecast
Access full Research: https://www.renub.com/global-vitiligo-market-p.php Vitiligo is a long-term skin disease in which patches of the skin lose their color. The skin patches affected by the disease Vitiligo become white. This happens because melanocytes within the skin die off. The skin pigmentation, melanin, due to which skin has its color, protection from sun UV rays this all happens because of melanocytes cells. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market. However, shortage of dermatologists and available treatments having longer duration of times are major challenges for the growth of this market. According to Renub Research global Vitiligo market will be US$ 2.4 Billion by the year 2024. Vitiligo disease prevalence varies between race, regions and countries. It is expected that overall prevalence fall between 1-2 percent of the total population. Although Vitiligo disease can arise at any age, it mostly occurs to young and middle age people. At present globally over 21 Million people has suffered from this diseases. Request a free sample copy of the report: https://www.renub.com/contactus.php Renub Research report titled “Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges” provides a complete analysis of global vitiligo drugs market.
85 views • 7 slides